| Item Type | Name |
|
Concept
|
Carcinoma, Squamous Cell
|
|
Academic Article
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
|
Academic Article
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Is patient travel distance associated with survival on phase II clinical trials in oncology?
|
|
Academic Article
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
|
Academic Article
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
|
|
Academic Article
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
|
Academic Article
|
The expanding role of systemic therapy in head and neck cancer.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
|
Academic Article
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
|
Academic Article
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
|
Academic Article
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
|
Academic Article
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
|
|
Academic Article
|
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries.
|
|
Academic Article
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
|
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Searching for a standard.
|
|
Academic Article
|
Expanding role of the medical oncologist in the management of head and neck cancer.
|
|
Academic Article
|
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
|
|
Academic Article
|
Current treatments and promising investigations in a multidisciplinary setting.
|
|
Academic Article
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
|
Academic Article
|
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
|
|
Academic Article
|
Curative treatment for advanced head and neck cancer in the community: has the time come?
|
|
Academic Article
|
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
|
|
Academic Article
|
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
|
|
Academic Article
|
Induction chemotherapy: to use or not to use? That is the question.
|
|
Academic Article
|
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
|
|
Academic Article
|
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Induction chemotherapy for head and neck cancer: recent data.
|
|
Academic Article
|
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
|
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
|
Academic Article
|
EGFR-directed treatments in SCCHN.
|
|
Academic Article
|
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
|
|
Academic Article
|
Competing roads to larynx preservation.
|
|
Academic Article
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
|
Academic Article
|
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
|
|
Academic Article
|
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
|
Academic Article
|
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
|
|
Academic Article
|
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
|
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
|
Academic Article
|
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
|
|
Academic Article
|
Reply to s. Chakraborty et al.
|
|
Academic Article
|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
|
|
Academic Article
|
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
HPV-Associated Head and Neck Cancer.
|
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
|
Academic Article
|
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
|
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
|
|
Academic Article
|
Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
|
|
Academic Article
|
Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population.
|
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
|
Academic Article
|
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
|
|
Academic Article
|
Management of Early Head and Neck Cancer in Elderly Patients.
|
|
Academic Article
|
Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
|
|
Academic Article
|
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
|
|
Academic Article
|
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
|
|
Academic Article
|
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
|
|
Academic Article
|
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
|
|
Academic Article
|
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
|
|
Academic Article
|
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
|
|
Academic Article
|
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
|
|
Academic Article
|
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
|
|
Academic Article
|
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
|
|
Academic Article
|
Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology.
|
|
Academic Article
|
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits.
|
|
Academic Article
|
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
|